Cargando…
Guselkumab for hidradenitis suppurativa in a patient with concomitant Crohn’s disease: Report and systematic literature review of effectiveness and safety
Guselkumab appears to be safe and effective in the treatment of patients with HS, who do not respond to adalimumab and other systemic therapies. Guselkumab can be used in patients with comorbid Crohn's disease.
Autores principales: | Jørgensen, Astrid‐Helene Ravn, Holm, Jesper Grønlund, Thomsen, Simon Francis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752321/ https://www.ncbi.nlm.nih.gov/pubmed/33363841 http://dx.doi.org/10.1002/ccr3.3090 |
Ejemplares similares
-
Liver enzyme levels are associated with markers of systemic inflammation, disease severity, and metabolic syndrome in patients with hidradenitis suppurativa
por: Nielsen, Valdemar Wendelboe, et al.
Publicado: (2021) -
Fatal outcome of malignant transformation of hidradenitis suppurativa: A case report and literature review
por: Nielsen, Valdemar Wendelboe, et al.
Publicado: (2020) -
Successful treatment of hidradenitis suppurativa and Crohn's disease with combined guselkumab and apremilast
por: Agud‐Dios, Manuel, et al.
Publicado: (2022) -
Therapeutic Response to Secukinumab in a 36-Year-Old Woman with Hidradenitis Suppurativa
por: Jørgensen, Astrid-Helene Ravn, et al.
Publicado: (2018) -
Adalimumab for the Treatment of Periodontitis in a 35-Year-Old Woman with Hidradenitis Suppurativa
por: Yao, Yiqiu, et al.
Publicado: (2023)